Chronic Heart Failure. Congestive heart failure.
Conditions
Interventions
Forty patients were randomized by drawing randomly and proportionally between the two arms of the study, characterized as aerobic exercise of moderate and high intensity. However, the patient was mask
Behavioural
Other
D010806
Sponsors
Núcleo de Cardiologia e Medicina do Exercício (NCME)
Universidade do Estado de Santa Catarina (UDESC)
Universidade Federal de Santa Catarina (UFSC)
Universidade Federal do Rio Grande do Sul (UFRGS)
Universidade de São Paulo (USP)
Eligibility
Sex/Gender
Male
Age
35 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients diagnosed with Chronic Heart Failure functional class II and III of Ischemic or hypertensive. Ejection fraction less than 45%. Male. Minimum age 35 years and and maximum of 80 years old. Clinically Stable and being Released by medical assistant to join the program of cardiopulmonary and metabolic rehabilitation through exercise. Not having made or had complications hospitalization in the last month. Sedentary.
Exclusion criteria
Exclusion criteria: To have present as uneventful clinical decompensation with or without hospitalization. Stop taking medicine without doctor consent. Introduced in acute inflammatory diseases. Being patient with primary pulmonary hypertension, pulmonary infections or active pulmonary thromboembolism. Being with clinically decompensated systolic blood pressure above 180mm Hg. Being patient with renal failure, unstable angina, ventricular arrhythmia, have histories of cardiac events (acute coronary syndrome, cardiac surgery, myocardial infarction) within the last four months. Introduced orthopedic or neurological limitations that prevent them from doing physical exercise.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is estimated that after 12 weeks of exercise training supervised will occur: it increase markers anti-inflammatory (cytokines: interleukin 10 and 4). Decrease markers pro-inflmatórios (cytokines: TNF alpha, one beta and inteleucina 6). It increase tolerance to exercise time during exercise testing with progressive loading, represented by peak oxygen consumption (peak VO2), it increase the volume of blood ejected by the left ventricle (ejection fraction in %), followed by further relaxation of the heart muscle (improvement of diastolic function). It decrease heart rate and resting blood pressure, an increase in peripheral blood flow arteries. It decrease cell death associated with increase anti-oxidant function and improvement in quality of life.;After the intervention period of 12 weeks was found increased anti-inflammatory marker (interleukin 10), together with a decrease in pro-inflammatories markers(TNF alpha, inteleucina 6), it was observed increase tolerance to exercise over time during the exercise test with progressive loading, it was represented by an increase in peak oxygen consumption (VO2 peak). It was also found the increase relaxation of the cardiac muscle, which represents an improvement in diastolic function. The decrease in heart rate and blood pressure in resting and the increase in peripheral arterial blood flow was observed at the end of the study. There was a decrease on cell death associated with increased anti-oxidant function. Finally it was found an improvement in quality of life. | — |
Countries
Brazil
Contacts
Public ContactAnderson;Tales Ulbrich;Carvalho
Núcleo de Cardiologia e Medicina do Exercício (NCME);Núcleo de Cardiologia e Medicina do Exercício (NCME)
Outcome results
None listed